Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 8/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28995764 | 1.00 | TRPA1 (0.46) | TRPA1AAK1S1PR3SCN9AACACB | |
| SCHEMBL25811104 | 0.88 | AAK1 (0.50) | TRPA1AAK1SCN9ACA1CA2 | |
| SCHEMBL18862943 | 0.86 | TRPA1 (0.46) | TRPA1AAK1S1PR3SCN9AACACB | |
| SCHEMBL28604827 | 0.86 | TRPA1 (0.46) | TRPA1AAK1S1PR3SCN9AACACB | |
| SCHEMBL25298000 | 0.84 | ACACB (0.39) | SCN9AACACBSMN1; SMN2 | |
| SCHEMBL25298001 | 0.84 | ACACB (0.39) | SCN9AACACBSMN1; SMN2 | |
| SCHEMBL18862946 | 0.83 | TRPA1 (0.43) | TRPA1AAK1S1PR3SCN9AACACB | |
| SCHEMBL25811855 | 0.83 | S1PR3 (0.47) | TRPA1AAK1S1PR3 | |
| SCHEMBL28995534 | 0.83 | S1PR3 (0.47) | TRPA1AAK1S1PR3 | |
| SCHEMBL28599748 | 0.82 | TRPA1 (0.43) | TRPA1AAK1S1PR3SCN9AACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583866-B2 | Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists | BEONE MEDICINES I GMBH (CH) | 2026-03-24 | — | — | US | disclosed |
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BEONE MEDICINES I GMBH (CH) | 2023-07-13 | — | — | US | disclosed |
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BEONE MEDICINES I GMBH (CH) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583866-B2 | Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists | BIRC2, BIRC3, BIRC5 | TRPA1 186/4885AAK1 506/4885S1PR3 2650/4885 |
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BIRC2, BIRC3, API5 | TRPA1 974/4885AAK1 293/4885S1PR3 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.